Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Subcutaneous Romiplostim Increased Platelet Response in Children with ITP

Conference Correspondent  - ASH

The thrombopoietin‒receptor agonist romiplostim is approved for adults with chronic immune thrombocytopenia (ITP). Several phase 1/2 and 3 studies have been conducted to investigate the efficacy and safety of romiplostim in children with ITP; the current single-arm, open-label, global study evaluated subcutaneous romiplostim for ≤3 years in 204 children with ITP.

Eligible children must have had ITP for ≥6 months, received ≥1 prior ITP therapies, and had a platelet count ≤30 × 109/L or uncontrolled bleeding at screening. Treatment consisted of weekly subcutaneous dosing initiated at 1 μg/kg and titrated weekly in 1-μg/kg increments up to 10 μg/kg to target platelet counts of 50 to 200 × 109/L. The primary end point was the percentage of time with a platelet response in months 0 to 6, with response defined as a platelet count ≥50 × 109/L with no rescue medications in the past 4 weeks.

At the interim data cutoff, 203 patients received ≥1 doses. The median age of the study population was 10 years (range, 1-17 years), 51% were female. The median ITP duration was 1.8 years (range, 0.5-13.8 years); median baseline platelet count was 14 × 109/L. Patients had received a median of 2 (range, 1-7) prior ITP treatments, 34 (17%) patients were receiving concurrent ITP medications, and 10 (5%) patients had had prior splenectomy.

During the first 6 months, the median percentage of time with a platelet response was 50% (17%, 83%); the percentage of time ≥100 × 109/L was 17% (0%, 33%). During months 7-12, the median percentage of time with platelet response was 83% (50%, 100%). Over the course of the study, 88% of patients responded; the median percentage of time ≥100 × 109/L was 26% (5%, 48%). The median percentage of time with an increase in platelet counts ≥20 × 109/L above baseline was 74% (39%, 90%). From week 12 onward, median platelet counts were >50 × 109/L. There was no variation in platelet response and dose by age. Four patients had treatment-free periods and maintained platelet counts ≥50 × 109/L with no ITP medications (including romiplostim) for ≥24 weeks. Fifty-two (26%) patients received rescue medications; 3 patients had splenectomy on study.

Median treatment duration was 53 (range, 8-119) weeks for a total exposure time of 226 patient-years. Over the course of the study, patients received a median average weekly romiplostim dose of 6.9 (0.2-9.5) µg/kg; the median dose was 9 μg/kg at 1 year (n = 106) and 10 μg/kg at 2 years (n = 17). The majority (63%) of patients initiated self-administration because their platelet count was ≥50 × 109/L. The most common adverse events of any grade included epistaxis (32%), headache (31%), and viral upper respiratory tract infection (28%). Serious adverse events occurred in 41 (20%) patients, including epistaxis (5%), decreased platelet count (3%), and thrombocytopenia (1%); of these, 5 serious adverse events were deemed treatment-related: 2 headaches, 2 abdominal pain, and 1 each of presyncope and neutralizing antibodies. Overall, 64 (31%) patients discontinued treatment, mostly due to lack of efficacy (n = 38); 7 patients discontinued due to adverse events, including headaches (n = 2), abdominal pain (n = 1), dizziness (n = 1), interstitial lung disease (n = 1), mixed connective tissue disease (n = 1), neutralizing antibody (n = 1), lupus (n = 1), and vomiting (n = 1). Bleeding occurred in 62% of patients, with grade ≥3 bleeding noted in 17 (8%) patients, including epistaxis (4%), ecchymosis (1%), and contusion (1%); grade 4 bleeding events were reported in 2 patients.

There were 6 cases of neutralizing antibody to romiplostim (of 201 patients tested), but none to thrombopoietin; all discontinued due to antibodies, 5/6 had continued elevated platelet counts, and in 2/6 cases, antibodies were not found on retesting. Of 30 patients with baseline bone marrow biopsies (all with modified Bauermeister scores of grade 0 [no reticulin], 1 [fine fibers], or 2 [fine fiber network]), 27 had evaluable on-study biopsies after 1 year; 1 patient had an increase from grade 0 to 2. There was no follow-up biopsy for this patient; once at a steady dose of 10 μg/kg, most (10/16) of his platelet counts were ≥30 × 109/L. Four patients had an increase in 1 grade, 1 patient had a decrease in 2 grades, and 3 had a decrease in 1 grade. There were no findings of collagen or abnormalities.

These results demonstrated that the majority of children with ITP who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 109/L from week 12 onward; no new safety signals were observed over 226 patient-years.

Grainger JD, et al. ASH 2017. Abstract 2334

Related Items
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Staying Abreast of New Treatments
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Managing Patients with Multiple Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Perceptions of Daratumumab Therapy
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Last modified: December 28, 2017